Clinical Trials

UnityPoint Health - John Stoddard Cancer Center

Clinical Trials and Research Studies

Research plays a large role in cancer care. Partnering with Iowa Oncology Research Association (IORA), UnityPoint Health – John Stoddard Cancer Center, a service of UnityPoint Health – Des Moines, is able to provide central Iowans with the opportunity to participate in over 100 national and international research studies. Through research, we have identified improved methods of treating patients. With continued investment in research, we look forward to the day when we can say we have a cure for cancer.

Clinical trials offer high-quality cancer care. Entry into a research study is always a joint decision between the physician and the patient. By looking at the pros and cons of clinical trials and your other treatment choices, you are taking an active role in a decision that affects your life. If you are interested in participating in a research study, please ask your physician to determine if there is a clinical trial appropriate for you, or call our research office at (515) 241-3305. 

The IORA has clinical trials available covering all areas of cancer treatment. Areas of research include: chemotherapy, radiation therapy, immunotherapy, surgery, symptom management and cancer prevention.

Policy on Financial Conflict of Interest in Research (FCOI)

Research Studies

Brain Cancer
BONE METASTASES

NRG-CC014: Radiation Therapy for High-Risk Asymptomatic Bone Metastases: A Pragmatic Multicenter Randomized Phase 3 Clinical Trial (PREEMPT) (NCT06745024)

BRAIN METASTASES

CE.7: A Phase III Trial of Stereotactic Radiosurgery Compared with Whole Brain Radiotherapy (WBRT) for 5-15 Brain Metastases (DCP) (NCT03550391)

GLIOBLASTOMA

A072201: Randomized Phase II Trial of Anti-Lag-3 and Anti-PD-1 Blockade verse SOC in Patients with Recurrent Glioblastoma (NCT06325683)

MENINGIOMA

NRG-BN003: Phase III Trial of Observation versus Irradiation for a Gross Totally Resected Grade II Meningioma (NCT03180268)

Breast Cancer
BONE METASTASES

NRG-CC014: Radiation Therapy for High-Risk Asymptomatic Bone Metastases: A Pragmatic Multicenter Randomized Phase 3 Clinical Trial (PREEMPT) (NCT06745024)

CANCER CONTROL

A212102: Blinded Reference Set for Multicancer Early Detection Blood Tests (NCT05334069)

A222101: An Early Phase and Phase II Clinical Trial to Evaluate Ganglioside-Monosialic Acid (GM1) for Preventing Paclitaxel-Associated Neuropathy (DCP) (NCT05751668)

NRG-CC011: Cognitive Training For Cancer Related Cognitive Impairment In Breast Cancer Survivors: A Multi-Center Randomized Double-Blinded Controlled Trial (DCP) (Temp closed to Accrual) (NCT05896189)

NRG-CC015: Harnessing E-Mindfulness Approaches for Living After Breast Cancer --- HEAL-ABC (DCP) (NCT06748222)

WF2304-A172401: Complementary Options for Symptom Management in Cancer (COSMIC): Assessing Benefits and Harms of Cannabis and Cannabinoid Use Among a Cohort of Cancer Patients Treated in Community Oncology Clinics (S2013 CO-ENROLLMENT ELIGIBLE) (NCT06418204)

ER+/HER2-

A012301: LoTam: A Randomized, Phase III Clinical Trial of Low-Dose Tamoxifen for Selected Patients with Molecular Low-Risk Early-Stage Breast Cancer (DCP) (Imaging Sub Study – Closed to Accrual) (NCT06671912)

HER2-

NRG-BR007: A Phase III Clinical Trial Evaluating De-Escalation of Breast Radiation for Conservative Treatment of Stage I, Hormone Sensitive, HER2-Negative, Oncotype Recurrence Score Less Than or Equal to 18 Breast Cancer (DEBRA) (NCT04852887)

S1703: Randomized Non-Inferiority Trial Comparing Overall Survival of Patients Monitored with Serum Tumor Marker Directed Disease Monitoring versus Usual Care in Patients with Metastatic Hormone Receptor Positive Breast Cancer (NCT03723928)

S2206: Phase III Trial of Neoadjuvant Durvalumab (NSC 778709) plus Chemotherapy versus Chemotherapy Alone for Adults with MammaPrint Ultrahigh (MP2) Hormone Receptor (HR) Positive / Human Epidermal Growth Factor Receptor (HER2) Negative Stage II-III Breast Cancer (NCT06058377)

MA.39: Tailor RT: Rand Trial of Regional Radiotherapy in Biomarker Low Risk Node Positive Breast Cancer (NODE + / LOW RISK) (DCP) (NCT03488693) 

HER2+

A012303: ShortStop-HER2: Shortened Duration of Adjuvant Therapy in Patients with Early-Stage HER2+ Breast Cancer Who Achieve pCR After Neoadjuvant Chemotherapy with HER2 Blockade (DCP) (NCT06876714) 

MOONSHOT

Moonshot NCI 10323: Cancer Moonshot Biobank Research Protocol (NCT04314401)

TRIPLE NEGATIVE

S2013: Immune Checkpoint Inhibitor Toxicity (I-CHECKIT): A Prospective Observational Study (DCP) (Cohort 1 Closed to Accrual) (NCT04871542)

S2212: Shorter Anthracycline-Free Chemo Immunotherapy Adapted to Pathological Response in Early Triple Negative Breast Cancer (SCARLET), A Randomized Phase III Study (DCP) (NCT05929768) 

A012103: OptimICE-PCR: De-Escalation of Therapy in Early-Stage TNBC Patients Who Achieve pCR After Neoadjuvant Chemotherapy with Checkpoint Inhibitor Therapy (DCP) (QOL Sub Study - Closed to Accrual) (NCT05812807)

Cancer Control
BONE METASTASES

NRG-CC014: Radiation Therapy for High-Risk Asymptomatic Bone Metastases: A Pragmatic Multicenter Randomized Phase 3 Clinical Trial (PREEMPT) (NCT06745024)

CANCER CONTROL

A211901: Reaching RURAL Cancer Survivors who Smoke Using Text-Based Cessation Interventions (DCP) (NCT05008848)

A222004: A Randomized Phase III Trial of Olanzapine versus Megestrol Acetate for Cancer-Associated Anorexia (DCP) (NCT04939090)

EAQ202: Improving Adolescent and Young Adult Self-Reported Data in ECOG-ACRIN Trials (DCP)(BREAST CANCER; NON-HISPANIC WHITE & LEUKEMIA/LYMPHOMA COHORTS CLOSED TO ACCRUAL) (NCT05108298)

NRG-GY022: Assessment of Carboplatin Clearance Predictors: A PK Study on NCI-Sponsored Clinical Trials or Standard of our Treatments Using Carboplatin (RE-OPENED TO MALE PATIENTS ONLY) (NCT03997370)

URCC-19185: Multicenter Randomized Controlled Trial Comparing Brief Behavioral Therapy for Cancer Related Insomnia (BBT-CI) and Healthy Eating Education Learning (HEAL) (DCP) (NCT04829539)

Gastrointestinal Cancer
BONE METASTASES

NRG-CC014: Radiation Therapy for High-Risk Asymptomatic Bone Metastases: A Pragmatic Multicenter Randomized Phase 3 Clinical Trial (PREEMPT) (NCT06745024)

CANCER CONTROL

A212102: Blinded Reference Set for Multicancer Early Detection Blood Tests (DCP) (NCT05334069)

WF-1806: Myopenia and Mechanisms of Chemotherapy Toxicity in Older Adults with Colorectal Cancer: The M&M Study (Age 60-74 stratum is Closed) (DCP) (NCT03998202)

COLON

NRG-GI008: Colon Adjuvant Chemotherapy Based on Evaluation of Residual Disease (CIRCULATE-NORTH AMERICA) (NCT05174169)

A022101: A Pragmatic Randomized Phase III Trial Evaluating Total Ablative Therapy for Patients with Limited Metastatic Colorectal Cancer: Evaluating Radiation, Ablation, and Surgery (ERASur) (DCP) (NCT05673148)

WF2304-A172401: Complementary Options for Symptom Management In Cancer (COSMIC): Assessing Benefits and Harms of Cannabis and Cannabinoid Use Among a Cohort of Cancer Patients Treated in Community Oncology Clinics (S2013 CO-ENROLLMENT ELIGIBLE) (NCT06418204)

ESOPHAGEAL & GASTRIC

S2013: Immune Checkpoint Inhibitor Toxicity (I-CHECKIT): A Prospective Observational Study (DCP) (COHORT 1 CLOSED) (WF-2304-A172401 CO-ENROLLMET ELIGIBLE) (NCT04871542)

A022102: Randomized Phase III Trial of mFOLFIRINOX +/- Nivolumab vs. FOLFOX +/- Nivolumab for First-Line Treatment of Metastatic HER2-Negative Gastroesophageal Adenocarcinoma (DCP) (NCT05677490)

EA2174: A Phase II/III Study of Peri-Operative Nivolumab and Ipilimumab in Patients with Locoregional Esophageal and Gastroesophageal Junction Adenocarcinoma (TEMP SUSPENDED) (NCT03604991)

S2303: Randomized Phase II/III Trial of 2nd Line Nivolumab + Paclitaxel + Ramucirumab versus Paclitaxel + Ramucirumab in Patients with PD- L1 CPS ≥ 1 Advanced Gastric and Esophageal Adenocarcinoma (PARAMUNE) (NCT06203600)

MOONSHOOT

Moonshot NCI 10323: Cancer Moonshot Biobank Research Protocol (NCT04314401)

PANCREATIC

EA2185: Comparing the Clinical Impact of Pancreatic Cyst Surveillance Programs and Associated Biomarkers (DCP) (NCT04239573)

A021806: A Phase III Trial of Perioperative Versus Adjuvant Chemotherapy for Resectable Pancreatic Cancer (DCP) NEW PATIENT ACCRUAL CLOSES 12/15/25 (NCT04340141)

A022106: Phase II/III Second-Line NABPLAGEM vs. Nab-Paclitaxel/Gemcitabine in BRCA1/2 or PALB2 Mutant Metastatic Pancreatic Ductal Adenocarcinoma (PLATINUM) (NCT06115499)

EA2192: APOLLO: A Randomized Phase II Double-Blind Study of Olaparib versus Placebo Following Adjuvant Chemotherapy in Patients with Resected Pancreatic Cancer and a Pathogenic BRC1, BRCA2 or PALB2 Mutation (NCT04858334)

NRG-GI011: Phase III Randomized Trial Dose Escalated Radiation in Locally Advanced Pancreas Cancer (LAPC) Patients (LAP100) (DCP) (NCT06958328)

RECTAL

A022101: A Pragmatic Randomized Phase III Trial Evaluating Total Ablative Therapy for Patients with Limited Metastatic Colorectal Cancer: Evaluating Radiation, Ablation, and Surgery (ERASur) (DCP) (NCT05673148)

WF2304-A172401: Complementary Options for Symptom Management In Cancer (COSMIC): Assessing Benefits and Harms of Cannabis and Cannabinoid Use Among a Cohort of Cancer Patients Treated in Community Oncology Clinics (S2013 CO-ENROLLMENT ELIGIBLE) (NCT06418204)

S2417CD: A Pragmatic Randomized Controlled Trial to Evaluate The Effectiveness of an Intervention called Current Together After Cancer (CTAC) to Promote Guideline-Concordant Colorectal Cancer Surveillance (NCT07018869)

SMALL BOWEL

S1922: Randomized Phase II Selection Study of Ramucirumab and Paclitaxel versus FOLFIRI in Refractory Small Bowel Adenocarcinoma (NCT04205968) 

Genitourinary Cancer

A212102: Blinded Reference Set for Multicancer Early Detection Blood Tests (DCP) (NCT05334069)

BLADDER

A032103: MODERN: An Integrated Phase 2/3 and Phase 3 Trial of MRD-Based Optimization of ADjuvant ThErapy in URothelial CaNcer (DCP) (NCT05987241)

S1937: Ph III Rand Trial of Eribulin (NSC #707389) w/ or w/o Gemcitabine vs Standard of Care (Physician’s Choice) for Treatment of Metastatic Urothelial Carcinoma Refractory to, or Ineligible for, ANTI PD1/PDL1 Therapy (DCP) (arm 2 closed to accrual) (NCT04579224)

NRG-GU015: The Phase III Adaptive Radiation and Chemotherapy for Muscle Invasive Bladder Cancer Trial (ARCHER) (DCP) (NCT07097142)

S2427: Single Arm Phase II Study of Bladder Preservation with Immunoradiotherapy After a Clinically Meaningful Response to Neoadjuvant Therapy in Patients with Muscle Invasive Bladder Cancer (BRIGHT) (NCT07061964)

BONE METASTASES

NRG-CC014: Radiation Therapy for High-Risk Asymptomatic Bone Metastases: A Pragmatic Multicenter Randomized Phase 3 Clinical Trial (PREEMPT) (NCT06745024)

KIDNEY

S1931: Phase III Trial of Immunotherapy-Based Combination Therapy With or Without Cytoreductive Nephrectomy for Metastatic Renal Cell Carcinoma (PROBE Trial) (DCP) (NCT04510597)

S2200: A Phase II Randomized Trial of Cabozantinib (NSC #761968) With or Without Atezolizumab (NSC #783608) in Patients with Advanced Papillary Renal Cell Carcinoma (PAPMET2) (NCT05411081)

MOONSHOOT

Moonshot NCI 10323: Cancer Moonshot Biobank Research Protocol (NCT04314401)

PROSTATE

NRG-GU008: Randomized Phase III Trial Incorporating Apalutamide and Advanced Imaging into Salvage Treatment for Patients with Node+ Prostate Cancer after Radical Prostatectomy (INNOVATE*) Intensifying Treatment for Node Positive Prostate Cancer by Varying the hormonal Therapy (DCP) (NCT04134260)

NRG-GU010: Parallel Phase III Rand Trial of Genomic Risk Stratified Unfavorable Intermediate Risk Prostate Cancer: De-Intensification and Intensification Clinical Trial Evaluation (GUIDANCE) (DCP)(INTENSIFICATION COHORT CLOSED) (NCT05050084)

NRG-GU011: A Phase II Double-Blinded, Placebo-Controlled Trial of Prostate Oligometastatic Radiotherapy with or without Androgen Deprivation Therapy in Oligometastatic Prostate Cancer (NRG PROMETHEAN) (NCT05053152)

S1802: Phase III Randomized Trial of Standard Systemic Therapy (SST) Versus Standard Systemic Therapy Plus Definitive Treatment (Surgery or Radiation) of the Primary Tumor in Metastatic Prostate Cancer (DCP) (NCT03678025)

CCTG-PR26: A Randomized Phase III Clinical Trial for the Addition of Docetaxel to Androgen Receptor Pathway Inhibitors in Patients with Metastatic Castration Sensitive Prostate Cancer and Suboptimal PSA Response (TRIPLE-SWITCH) (NCT06592924)

PSMACare: An International Prospective Open-Label, Multi-Center, Randomized, Non-Comparative Phase II Study of Lutetium Vipivotide Tetraxetan Alone and Lutetium Vipivotide Tetraxetan in Combination with Androgen Receptor Pathway Inhibitors in Patients with PSMA PET Scan Positive Castration-Resistant Prostate Cancer (NCT05849298)

RENAL CELL

A031801: Phase II Randomized Trial of Radium-223 Dichloride and Cabozantinib in Patients with Advanced Renal Carcinoma with Bone Metastasis (RadiCal) (NCT04071223)

NRG-GU012: Randomized Phase II Stereotactic Ablative Radiation Therapy (SABR) for Metastatic Unresected Renal Cell Carcinoma (RCC) Receiving Immunotherapy (SAMURAI) (NCT05327686)

Gynecologic Cancer
BONE METASTASES

NRG-CC014: Radiation Therapy for High-Risk Asymptomatic Bone Metastases: A Pragmatic Multicenter Randomized Phase 3 Clinical Trial (PREEMPT) (NCT06745024)

GERM CELL TUMORS

AGCT1531: A Phase 3 Study of Active Surveillance for Low Risk and a Randomized Trial of Carboplatin vs. Cisplatin for Standard Risk Pediatric and Adult Patients with Germ Cell Tumors (DCP) (STRATUM 2 is Temporarily Closed) (NCT03067181)

MOONSHOOT

Moonshot NCI 10323: Cancer Moonshot Biobank Research Protocol (NCT04314401)

A212102: Blinded Reference Set for Multicancer Early Detection Blood Tests (DCP) (NCT05334069)

Head and Neck Cancer
BONE METASTASES

NRG-CC014: Radiation Therapy for High-Risk Asymptomatic Bone Metastases: A Pragmatic Multicenter Randomized Phase 3 Clinical Trial (PREEMPT) (NCT06745024)

SALIVARY GLAND

NRG-HN010: A Phase II Trial of HER2-Targeted Therapies for Recurrent, Metastatic or Unresectable HER2-Expressing Salivary Gland Cancers (NCT05408845)

HNSCC

EA3191: A Phase II Randomized Trial of Adjuvant Therapy with Pembrolizumab after Resection of Recurrent / Second Primary Head and Neck Squamous Cell Carcinoma with High Risk Features (NCT04671667)

EA3211: Phase III Randomized Trial of Immunotherapy with or Without Consolidative Radiotherapy for Oligometastatic Head and Neck Squamous Cell Carcinoma (DCP) (NCT05721755) 

NRG-HN009: Rand Phase II/III Trial of Radiation with High-Dose Cisplatin (100 mg/m2) Every Three Weeks vs Radiation with Low-Dose Weekly Cisplatin (40mg/m2) for Patients with Locoregionally Advanced Squamous Cell Carcinoma of the Head & Neck (TEMPORARILY CLOSED TO ACCRUAL) (NCT05050162)

EA3132: Phase II Randomized Trial of Radiotherapy With or Without Cisplatin for Surgically Resected Squamous Cell Carcinoma of the Head and Neck (SCCHN) with TP53 Sequencing (NCT02734537)

NRG-CC013: A Randomized, Masked, Placebo Controlled, Phase II Trial of Concurrent Chemoradiation With BMX-001 In Patients With Head And Neck Squamous Cell Carcinoma Receiving Concurrent Chemoradiation (DCP) (NCT06532279)

Nasopharyngeal

A092105: Randomized Phase 2 Study of Nivolumab and Ipilimumab with or Without Cabozantinib in Patients with Advanced Nasopharyngeal Carcinoma That Have Progressed After Platinum Treatment and Immunotherapy (NCT05904080)

OROPHARYNGEAL

EA3161: A Phase III Randomized Study of Maintenance Nivolumab Versus Observation in Patients with Locally Advanced, Intermediate Risk HPV Positive OPSCC (NCT03811015)

A212102: Blinded Reference Set for Multicancer Early Detection Blood Tests (DCP) (NCT05334069)

EA3132: Phase II Randomized Trial of Radiotherapy with or without Cisplatin for Surgically Resected Squamous Cell Carcinoma of the Head and Neck (SCCHN) with TP53 Sequencing (NCT02734537)

Hematologic Cancer

A212102: Blinded Reference Set for Multicancer Early Detection Blood Tests (DCP) (NCT05334069)

AMYLOIDOSIS

S2213: A Phase III, Randomized Study of Daratumumab, Cyclophosphamide, Bortezomib and Dexamethasone (Dara-VCD) Induction Followed by Autologous Stem Cell Transplant or Dara-VCD Consolidation and Daratumumab Maintenance in Patients with Newly Diagnosed AL Amyloidosis (DCP) (NCT06022939)

CANCER CONTROL

URCC-24060: Impact of Targeted Therapy on Cancer-Related Cognitive Impairment (DCP)

CHRONIC LYMPHOCYTIC LEUKEMIA / SMALL LYMPHOCYTIC LYMPHOMA (CLL/SLL)

S1925: Randomized, Phase III Study of Early Intervention with Venetoclax and Obinutuzumab Versus Delayed Therapy with Venetoclax and Obinutuzumab in Newly Diagnosed Asymptomatic High-Risk Patients with Chronic Lymphocytic Leukemia / Small Lymphocytic Lymphoma (CLL/SLL): EVLOVE CLL/SLL Study (DCP) (NCT04269902)

CNS LYMPHOMA

A051901: Phase I Trial of Methotrexate, Rituximab, Lenalidomide, and Nivolumab (Nivo-MR2) Induction Followed by Lenalidomide and Nivolumab Maintenance in Primary CNS Lymphoma (NCT04609046) 

FOLLICULAR LYMPHOMA

S2308: Randomized Phase III Study of Mosunetuzumab vs. Rituximab for Low Tumor Burden Follicular Lymphoma (NCT06337318)

HODGKIN’S LYMPHOMA

AHOD2131: A Randomized Phase 3 Interim Response Adapted Trial Comparing Standard Therapy with Immuno-oncology Therapy for Children and Adults with Newly Diagnosed Stage I and II Classic Hodgkin Lymphoma (DCP) (NCT05675410)

MANTLE CELL LYMPHOMA

A052101: A Randomized Phase 3 Trial of Continuous vs. Intermittent Maintenance Therapy with Zanubrutinib as Upfront Treatment in Older Patients with Mantle Cell Lymphoma (DCP) (NCT05976763)

MULTIPLE MYELOMA (MM)

EAA181: Effective Quadruplet Utilization After Treatment Evaluation (EQUATE): A Randomized Phase 3 Trial for Newly Diagnosed Multiple Myeloma Not Intended for Early Autologous Transplantation (DCP) (NCT04566328) 

S2209: A Phase III Randomized Trial for Newly Diagnosed Multiple Myeloma (NDMM) Patients Considered Frail or in a Subset of "Intermediate Fit" Comparing Upfront Three-Drug Induction Regimens Followed by Double or Single-Agent Maintenance (DCP) (NCT05561387)

A062102: Randomized Phase 2 Study of Iberdomide Maintenance Therapy Following Idecabtagene Vicleucel CAR-T in Multiple Myeloma Patients (NCT06179888)

MOONSHOOT

Moonshot NCI 10323: Cancer Moonshot Biobank Research Protocol (NCT04314401)

NON-HODGKIN’S LYMPHOMA

WF2304-A172401: Complementary Options for Symptom Management In Cancer (COSMIC): Assessing Benefits and Harms of Cannabis and Cannabinoid Use Among a Cohort of Cancer Patients Treated in Community Oncology Clinics (S2013 CO-ENROLLMENT ELIGIBLE) (NCT06418204)

SMOLDERING MYELOMA

EAA173: Daratumumab to Enhance Therapeutic Effectiveness of Revlimid in Smoldering Myeloma (DETER-SMM) (DCP) (NCT03937635)

Lung Cancer
BONE METASTASES

NRG-CC014: Radiation Therapy for High-Risk Asymptomatic Bone Metastases: A Pragmatic Multicenter Randomized Phase 3 Clinical Trial (PREEMPT) (NCT06745024)

NON-SMALL CELL

A081801: Integration of Immunotherapy Into Adjuvant Therapy for Resected NSCLC: ALCHEMIST Chemo-IO (DCP) (NCT04267848)  

EA5182: Randomized Phase III Study of Combination Osimertinib (AZD9291) and Bevacizumab Versus Osimertinib (AZD9291) Alone as First-Line Treatment for Patients with Metastatic EGFR-Mutant Non-Small Cell Lung Cancer (DCP) (NCT04181060) 

LUNG-MAP: A Master Protocol to Evaluate Biomarker-Driven Therapies and Immunotherapies in Previously-Treated Non-Small Cell Lung Cancer (Lung-MAP Screening Study) (DCP) (NCT03851445)

NRG-LU008: Phase III Prospective Randomized Trial of Primary Lung Tumor Stereotactic Body Radiation Therapy Followed by Concurrent Mediastinal Chemoradiation for Locally-Advanced Non-Small Cell Lung Cancer (DCP) (NCT05624996)

S1900G: A Randomized Phase II Study of Capmatinib Plus Osimertinib with or Without Ramucirumab in Participants with EGFR-Mutant, MET-Amplified Stage IV or Recurrent Non-Small Cell Lung Cancer (Lung-MAP Sub-Study) (NCT05642572)

S1900K: A Randomized Phase II Study of Tepotinib with or Without Ramucirumab in Participants with MET Exon 14 Skipping Positive Stage IV or Recurrent Non-Small Cell Lung Cancer (LUNG-MAP SUB-STUDY) (NCT06031688)

S1933: Pilot Study of Hypofractionated Radiotherapy Followed by Atezolizumab Consolidation in Stage II or III NSCLC Patients with Borderline Performance Status (NCT04310020)

S2013: Immune Checkpoint Inhibitor Toxicity (I-CHECKIT): A Prospective Observational Study (DCP) (WF2304-A172401 CO-ENROLLMENT ELIGIBLE) (NCT04871542)

MOONSHOT

Moonshot NCI 10323: Cancer Moonshot Biobank Research Protocol (NCT04314401)

SMALL CELL

NRG-LU007: Randomized Phase II/III Trial Of Consolidation Radiation + Immuno-therapy for ES-SCLC: RAPTOR trial (NCT04402788)

S1827: MRI Brain Surveillance Alone vs MRI Surveillance and Prophylactic Cranial Irradiation (PCI): A Rand Phase III Trial in Small-Cell Lung Cancer (MAVERICK) (NCT04155034)

S2013: Immune Checkpoint Inhibitor Toxicity (I-CHECKIT): A Prospective Observational Study (DCP) (NCT04871542)

A212102: Blinded Reference Set for Multicancer Early Detection Blood Tests (DCP) (NCT05334069)

S2409: PRISM: Precision in SCLC Via a Multicohort Study: Randomized Phase II Studies Evaluating Maintenance Durvalumab with or without Biomarker-Directed Therapy for Extensive Stage Small Cell Lung Cancer (ES-SCLC) (NCT06769126)

Neuroendocrine Cancer
BONE METASTASES

NRG-CC014: Radiation Therapy for High-Risk Asymptomatic Bone Metastases: A Pragmatic Multicenter Randomized Phase 3 Clinical Trial (PREEMPT) (NCT06745024)

CANCER CONTROL

A021901: Randomized Phase II Trial of Lutetium Lu 177 Dotatate Versus Everolimus in Somatostatin Receptor Positive Bronchial Neuroendocrine Tumors (NCT04665739)

S2012: Randomized Phase II/III Trial of First Line Platinum/Etoposide with or without Atezolizumab in Patient with Poorly Differentiated Extrapulmonary Small Cell Neuroendocrine Carcinomas (NEC) (NCT05058651)

Sarcoma
BONE METASTASES

NRG-CC014: Radiation Therapy for High-Risk Asymptomatic Bone Metastases: A Pragmatic Multicenter Randomized Phase 3 Clinical Trial (PREEMPT) (NCT06745024)

Skin Cancer
BONE METASTASES

NRG-CC014: Radiation Therapy for High-Risk Asymptomatic Bone Metastases: A Pragmatic Multicenter Randomized Phase 3 Clinical Trial (PREEMPT) (NCT06745024)

MELANOMA 

WF2304-A172401: Complementary Options for Symptom Management In Cancer (COSMIC): Assessing Benefits and Harms of Cannabis and Cannabinoid Use Among a Cohort of Cancer Patients Treated in Community Oncology Clinics (S2013 CO-ENROLLMENT ELIGIBLE) (NCT06418204)

MOONSHOT

Moonshot NCI 10323: Cancer Moonshot Biobank Research Protocol (NCT04314401)

Clinical Trial Resources